| High ACT score is not sufficient to reduce the risk of asthma exacerbations in asthma with low lung function Author links open overlay panelJae-WooKwonaHeewonJungbSae-HoonKimcYoon-SeokChangcYou SookChobDong-HoNahmdAn-SooJangeJung-WonParkfHo JooYoongSang-HeonChocYoung-JooChohByoung WhuiChoiiHee-BomMoonbTae-BumKimbPersonEnvelopeCOREA investigatorsj Show ShareShare Cited ByCite https://doi.org/10.1016/j.rmed.2019.02.010Get rights and content Under an Elsevier user license Open archive Highlights• Maintaining Asthma Control Test™(ACT) ≥ 20 could reduce the risk of asthma exacerbation in asthmatic patients with low FEV1. •The risk seems still higher in those patients than asthmatics with near-normal FEV1 despite asthma treatments by specialists. •Additional treatment strategies to prevent AEs seem to be needed for patients with low FEV1. AbstractBackgroundLow forced expiratory volume in 1 s (FEV1) is a risk factor for asthma exacerbations (AEs). We aimed to determine if asthma control could reduce the future risk of AEs in patients with low FEV1. This study was conducted to evaluate the future risks of AEs within six months according to Asthma Control Test™ (ACT) score and FEV1. MethodsA total of 565 patients with asthma were enrolled from the COREA cohort. The ACT score, lung function test, and number of AEs were assessed at baseline, three-month follow-up, and six-month follow-up with conventional asthma treatments by asthma specialists in real clinical settings. ResultsFemale sex, low ACT score, low FEV1, low FVC, and AE history in the previous three months were related with increased AEs within six months. AEs during six-month follow-up occurred in 24% of patients with ACT <20 and FEV1 < 60% at baseline. Among patients with an ACT score ≥20, 3.4% of patients with an FEV1 < 2.16 L and 9.8% of patients with FEV1 ≥ 2.16 L had experienced AEs (P = 0.01), although no differences were observed in the presence of AEs within six months according to the predicted FEV1 (FEV1 ≥ 60% vs. FEV1 < 60%, 5.66% vs. 8.51%, P = 0.65). ConclusionPatient with low FEV1 seemed to show higher risk of AEs than those with near-normal FEV1 despite ACT score ≥20 and asthma treatments. Therefore, treatment strategies that prevent AEs are needed in high-risk asthmatic patients. Measurement of cardiovascular and pulmonary function endpoints and other physiological effects following partial or complete substitution of cigarettes with electronic cigarettes in adult smokersAuthor links open overlay panelCarl D.D'RuizaPersonEnvelopeGrantO'ConnellbPersonEnvelopeDonald W.GraffcEnvelopeX. SherwinYandEnvelope Show moreNavigate DownShareShare Cited ByCite https://doi.org/10.1016/j.yrtph.2017.05.002Get rights and content Under a Creative Commons license Open access Highlights• Switching to e-cigarettes led to small improvements in cardiovascular and pulmonary function. •Reductions in vital signs were observed in most subjects that switched to using e-cigarettes. •Use of e-cigarettes for 5 days did not lead to negative respiratory health outcomes. •Physiological changes associated with smoking reduction were noted in exhaled breath. •Short-term use of e-cigarettes did not result in any serious adverse effects. AbstractAcute changes in select physiological parameters associated with cardiovascular physiology (systolic and diastolic blood pressure (BP) and heart rate (HR)), pulmonary function (FVC, FEV1, and exhaled CO and NO) and adverse events were measured in 105 clinically confined subjects who were randomized into groups that either completely or partially switched from conventional cigarettes to e-cigarettes or completely discontinued using tobacco and nicotine products altogether. Use of the e-cigarettes for five days under the various study conditions did not lead to higher BP or HR values, negative respiratory health outcomes or serious adverse health events. Reductions in BP and HR vital signs were observed in most of the participants that either ceased tobacco and nicotine products use altogether or switched completely to using e-cigarettes. Pulmonary function tests showed small but non-statistically significant improvements in FVC and FEV1 measurements in most use groups. Statistically significant (p < 0.05) benefits associated with smoking reduction were also noted in exhaled CO and NO levels. All study products were well tolerated. The study findings suggest that there are potential cardiovascular and pulmonary function benefits when smokers switch to using e-cigarette products. This further reinforces the potential that e-cigarettes offer smokers seeking an alternative to conventional tobacco products. What does a pulmonary function test diagnose?Pulmonary function tests are done to: Diagnose certain types of lung disease, such as asthma , bronchitis , and emphysema. Find the cause of shortness of breath. Measure whether exposure to chemicals at work affects lung function.
What does a pulmonary function test measure quizlet?It measures lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled.
What are the three 3 categories of pulmonary function testing?They include:. Spirometry. the most common type of lung function test. ... . Lung volume test. also known as body plethysmography. ... . Gas diffusion test. This test measures how oxygen and other gases move from the lungs to the bloodstream.. Exercise stress test. This test looks at how exercise affects lung function.. What is the most common of the pulmonary function test?Lung function tests (also called pulmonary function tests) include a variety of tests that check how well the lungs work. The most basic test is spirometry. This test measures the amount of air the lungs can hold. The test also measures how forcefully one can empty air from the lungs.
|
